Literature DB >> 27752863

Effects of daily tadalafil on lower urinary tract symptoms in young men with multiple sclerosis and erectile dysfunction: a pilot study.

D Francomano1, A Ilacqua1, A Cortese2, G Tartaglia2, A Lenzi1, M Inghilleri2, A Aversa3,4.   

Abstract

PURPOSE: Men affected by multiple sclerosis often experience neurogenic overactive bladder (OAB), lower urinary tract symptoms and erectile dysfunction (ED). The aim of the study was to investigate modifications of urinary and sexual functions after administration of daily tadalafil (TAD) 5 mg.
METHODS: Twenty men were enrolled in a single-blind, 4-week prospective study while 10 men without treatment served as controls. Primary outcomes were changes from baseline of International Prostate Symptom (IPSS), OAB questionnaire (OAB-q-short form) and International Index of Erectile Function (IIEF-5) scores. To evaluate the influence of bladder filling on somatic reflexes, we studied variations of the H-reflex evoked by electrical stimuli applied to the tibial nerve at the popliteal fossa and recorded from the soleus muscle. Also testosterone/estradiol (T/E) ratio was measured before and after treatment.
RESULTS: In TAD group, an improvement in IPSS (p < 0.001), OAB-q (p < 0.001) and IIEF-5 (p < 0.001) scores was found. Also, an increase in Q max (p < 0.01) and T/E ratio (p < 0.01) was found with a concomitant reduction in post-void residual volume (p < 0.001) without any changes in the H-reflex.
CONCLUSIONS: The study demonstrates for the first time that daily TAD in patients with multiple sclerosis improves storage symptoms, post-void residual volume, steroid hormone pattern and ED without urodynamic changes.

Entities:  

Keywords:  Estradiol; H-reflex; LUTS; Neurogenic bladder; Testosterone

Mesh:

Substances:

Year:  2016        PMID: 27752863     DOI: 10.1007/s40618-016-0557-y

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  27 in total

Review 1.  Bladder afferent signaling: recent findings.

Authors:  Anthony Kanai; Karl-Erik Andersson
Journal:  J Urol       Date:  2010-02-19       Impact factor: 7.450

2.  Nitric oxide modulates Ca(2+) channels in dorsal root ganglion neurons innervating rat urinary bladder.

Authors:  N Yoshimura; S Seki; W C de Groat
Journal:  J Neurophysiol       Date:  2001-07       Impact factor: 2.714

3.  Testosterone:estradiol ratio changes associated with long-term tadalafil administration: a pilot study.

Authors:  Emanuela A Greco; Marcello Pili; Roberto Bruzziches; Giovanni Corona; Giovanni Spera; Antonio Aversa
Journal:  J Sex Med       Date:  2006-07       Impact factor: 3.802

Review 4.  Antimuscarinic mechanisms and the overactive detrusor: an update.

Authors:  Karl-Erik Andersson
Journal:  Eur Urol       Date:  2010-12-08       Impact factor: 20.096

5.  Nitric oxide/cyclic guanosine monophosphate signalling mediates an inhibitory action on sensory pathways of the micturition reflex in the rat.

Authors:  Romain Caremel; Stephanie Oger-Roussel; Delphine Behr-Roussel; Philippe Grise; François A Giuliano
Journal:  Eur Urol       Date:  2010-08-02       Impact factor: 20.096

Review 6.  Mechanisms and current treatments of urogenital dysfunction in multiple sclerosis.

Authors:  Oscar Fernández
Journal:  J Neurol       Date:  2002-01       Impact factor: 4.849

Review 7.  Treatment of erectile dysfunction and lower urinary tract symptoms by phosphodiesterase inhibitors.

Authors:  Stefan Uckert; Christian G Stief
Journal:  Handb Exp Pharmacol       Date:  2011

8.  Neurokinins inhibit low threshold inactivating K+ currents in capsaicin responsive DRG neurons.

Authors:  Adrian Sculptoreanu; Debra E Artim; William C de Groat
Journal:  Exp Neurol       Date:  2009-07-23       Impact factor: 5.330

9.  Effects of inhibition of the L-arginine/nitric oxide pathway in the rat lower urinary tract in vivo and in vitro.

Authors:  K Persson; Y Igawa; A Mattiasson; K E Andersson
Journal:  Br J Pharmacol       Date:  1992-09       Impact factor: 8.739

10.  Cannabinoid-induced effects on the nociceptive system: a neurophysiological study in patients with secondary progressive multiple sclerosis.

Authors:  Antonella Conte; Chiara Marini Bettolo; Emanuela Onesti; Vittorio Frasca; Elisa Iacovelli; Francesca Gilio; Elena Giacomelli; Maria Gabriele; Massimiliano Aragona; Valentina Tomassini; Patrizia Pantano; Carlo Pozzilli; Maurizio Inghilleri
Journal:  Eur J Pain       Date:  2008-07-07       Impact factor: 3.931

View more
  6 in total

Review 1.  Erectile Dysfunction and Lower Urinary Tract Symptoms.

Authors:  Cosimo De Nunzio; Riccardo Lombardo; Giorgia Tema; Andrea Tubaro
Journal:  Curr Urol Rep       Date:  2018-06-01       Impact factor: 3.092

Review 2.  Lower urinary tract dysfunction in common neurological diseases.

Authors:  Mohamad Moussa; Athanasios Papatsoris; Mohamed Abou Chakra; Yousef Fares; Athanasios Dellis
Journal:  Turk J Urol       Date:  2020-04-30

Review 3.  The Management of Lower Urinary Tract Dysfunction in Multiple Sclerosis.

Authors:  Jure Tornic; Jalesh N Panicker
Journal:  Curr Neurol Neurosci Rep       Date:  2018-06-28       Impact factor: 5.081

4.  Managing Urological Disorders in Multiple Sclerosis Patients: A Review of Available and Emerging Therapies.

Authors:  Riccardo Bientinesi; Carlo Gandi; PierFrancesco Bassi
Journal:  Int Neurourol J       Date:  2020-06-30       Impact factor: 2.835

5.  Lower urinary tract symptoms and sexual dysfunction in men with multiple sclerosis.

Authors:  André Luiz Farinhas Tomé; Eduardo P Miranda; José de Bessa Júnior; Carlos Alberto Bezerra; Antônio Carlos Lima Pompeo; Sidney Glina; Cristiano Mendes Gomes
Journal:  Clinics (Sao Paulo)       Date:  2019-03-14       Impact factor: 2.365

Review 6.  The most effective sexual function and dysfunction interventions in individuals with multiple sclerosis: A systematic review and meta-analysis.

Authors:  Bahare Afshar; Leila Amini; Maryam Hasani; Shayesteh Jahanfar; Seyed Massood Nabavi
Journal:  Int J Reprod Biomed       Date:  2022-05-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.